NALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT
|
|
- Rosalyn Robbins
- 8 years ago
- Views:
Transcription
1 NALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT Opioid dependence is a devastating and frequently fatal medical condition. It is a manifestation of addictive disorder and characterized by denial and frequent violations of the morals, values and beliefs of the patient with the disease. A chilling question sometimes presented to the patient is, How many dead friends do you have? The response is often much more chilling. Since approximately 1986 we have employed a Naltrexone induced detoxification as the preferred method for detoxification from Opioids. The initial effort came from a sense of the difficulty that patients dependent on opioids presented when attempting abstinence based treatment, which was and is our orientation. These difficulties were exemplified by drug seeking as well as disruptive behavior and self focused irritability. The staff efforts required to deal with Opioid dependent patients were in excess of efforts required to deal with patients dependent upon alcohol, other sedative hypnotics or stimulants. Following some initial publications by Gold, et al related to the use of Clonidine to modify the symptoms of detoxification and following a review of a NIDA Monograph on Buprenorphine, we developed a protocol characterized by a brief stabilization on Buprenorphine followed by Naltrexone induced detoxification. The author has used this protocol in several facilities both freestanding and medical-surgical hospital based. This experience has informed an understanding of detoxification from Opioids. The success of the first few detoxifications was salutatory and possibly serendipitous in that there were dramatic results and the induced symptoms were easily manageable. As distinct from other Opioid addicts admitted to the facility, those who received the Naltrexone induced detoxification in fact, became indistinguishable in their group participation and enthusiasm for recovery within three to five days. Prior to this, Opioid addicts would typically be difficult for the majority of their stay in treatment and only be participatory in the last week or ten days of a four-week stay. Following Naltrexone induced detoxification, these patients were participatory and enthusiastic for the majority of their inpatient time. This experience of shortened detoxification and early enthusiastic participation in treatment has been consistent over the entire experience of using a Naltrexone induced protocol. The protocol has evolved over time. Figure 1 is a current order set provided to the nursing staff to initiate the process. When a change in staff has occurred or when the author has utilized a new facility there has been a significant learning curve for the nursing and support staff. However, this learning curve was relatively brief (several weeks) and, subsequently, nursing staff has competently handled the most difficult of presentations involving the physician in crisis management only at such times as the patient s response to the protocol was severe or unusual. From very early in this experience the facility used has been capable of lockdown if necessary. Earlier facilities were typically unlocked but could be locked if a particular patient s behavior required this response. This is mentioned because of the rather
2 Figure 1 ON ADMISSION IN ADDITION TO ROUTINE ADMIT ORDERS 1. Buprenorphine (Subutex) 2mg q2h prn pulse > 90, diastolic > 90, diaphoresis or restlessness. 2. Thorazine 50mg IM or PO Q6h prn nausea or vomiting or agitation. 3. Bentyl 20mg IM or PO Q6h prn cramping abdominal pain. 4. Zanaflex 8mg Q4h prn skeletal muscle cramps, diaphoresis, piloerection or signs or symptoms of opiate detoxification. 5. Imodium caps 2 Q6h prn diarrhea. 6. Seroquel 100mg PO qhs. Observe for orthostatic hypotension. 7. Catapres 0.1mg q1/2h prn pulse >80 up to 2.4mg/24 hrs. 8. Sandostatin 100mcg SC q4h prn nausea, vomiting or diarrhea. IF SEDATIVE AND/OR ALCOHOL DEPENDENCE ALSO PRESENT 1. Phenobarbital 90mg PO on admit and 6am, 2pm and 10pm 2. Phenobarbital 90mg PO q2h prn pulse >90, up to 4 prn doses in 24 hours. WHEN READY TO START DETOX (next morning, usually) 1. Xanax 2mg PO now. 2. Zanaflex 8mg PO now. 3. Bentyl 20mg IM now. 4. Thorazine 50mg IM now. 5. Sandostatin 100mcg SC now. 6. Imodium caps 2 now. 7. Buprenorphine 2mg SL now. 8. Naltrexone 150mg PO in ½ hour and 50mg qam. 9. DC Buprenorphine after above. 10. Catapres 0.2mg with first dose of Naltrexone and continue previous prn Catapres order. 11. Notify for pulse over 90 or diastolic over Xanax 2mg PO q2h prn agitation in next 12 hours only, up to four prn doses total. 13. DC all prn s 72 hours following first dose of Naltrexone.
3 consistent behavioral findings typical of induced Opioid detox. The patient responses over time, although with many individual examples of more severe and less severe reaction or difference in presentation, have been generally consistent. The initial process is stabilization on Buprenorphine, which may be for a period of 12 to 72 hours, depending on the potency, half-life and daily milligram dose of the Opioid that had been used. The rationale for a brief (12 hour) stabilization has been an idea that detoxification would be mild and easily manageable and the patient able to tolerate the procedure with reduced difficulty. This judgment has been based on the experience of detoxification in people who are young, healthy, have used Hydrocodone or Oxycodone compound tablets, Meperidine or Codeine. Generally such patients can be detoxified after orders written at the time of initial physician assessment, usually the day following admission, and this group of patients has not presented particular problems in management. A decision to stabilize a patient on Buprenorphine for up to72 hours would be based on medical comorbidities or the use of high doses of Opioids with a long halflife such as Methadone or high doses of sustained release Oxycodone. More recent experience would suggest that a high dose use history of Fentanyl might be best treated with a longer Buprenorphine stabilization also, although the understanding of this seems paradoxical because of the short half-life of Fentanyl. During the period of stabilization on Buprenorphine, as necessary (prn) medications are provided for the usual symptoms of detoxification, which includes antispasmodics, skeletal muscle relaxers, non-steroidal anti-inflammatory analgesics and Clonidine. At the time that induction to Naltrexone begins, the patient is preloaded with detoxification symptom specific medications as well as a mild dose of Alprazolam (2mg.) One-half hour later an initial dose of 150mg. of Naltrexone and a loading dose of Clonidine are provided by mouth. The emphasis to the nursing staff during the initial several hours of detoxification is that detoxification is best managed with frequent and liberal administration of Clonidine. A guideline is up to 0.1-mg. each one-half hour as symptoms persist up to a total daily dose of 2.4-mg. The provision of Clonidine is effective at these doses in relieving the majority of the symptoms of detoxification, however frequently induces orthostatic hypotension such that many patients require oneto-one staff attention during the first several hours. If the patient has been using high doses of Methadone or sustained release Oxycodone, a second dose of 100-mg. of Naltrexone is provided two hours after the initial dose. The typical symptoms of detoxification that are observed include marked restlessness with the patient moving about in bed and unable to remain still. Typically, patients are sedated enough that they appear to be sleeping fitfully. Occasionally, frank hallucinations occur in the context of pulse and blood pressure that is maintained at normal. The most disturbing symptoms that occur during detoxification are incontinence. This, of course, is disturbing to the dignity of the patient and difficult for the staff to deal with. Another disturbing symptom that occurs during this time is vomiting. Control of vomiting has rarely been difficult but often requires administration of injectable antiemetics, antispasmodics and non-specific anti-nausea medications as identified in Figure 1.
4 The length of expected physical symptoms of detoxification ranges from 3 24 hours. Most typically, patients have gotten through it or calm down within the first six hours. (A not very sensitive but descriptive language has developed among the staff to describe some of the observations. The author has typically received communications such as He s still flopping or he s done at times of ongoing medical symptoms or at completion of the severe symptoms of detoxification respectively.) When these symptoms resolve, the effect of sedatives administered usually result in a period of sleep that lasts 6 12 hours. During all stages of the protocol the patient is easily aroused and responds to verbal interaction although, occasionally, is obviously confused. The more informative experience, however, has been what follows the symptoms of physical detoxification. For the next hours the patient may have some residual mild symptoms of detoxification. Frequently these are muscle cramps, bone aches and sometimes rebound symptoms of a pain condition for which they were originally prescribed Opioids. Much more significantly, patients exhibit a period of anergy and anhedonia following awakening from their detoxification. This anergy and anhedonia lasts for 6 48 hours depending upon the drugs that have been used and idiosyncratic factors that have resisted clarification. Following the resolution of this period, the patients generally begin to feel well and even vigorous. During this period of returning physical improvement there is a period of irritability and agitation that can last another 6 72 hours depending upon the drug used, dose and idiosyncratic factors that have resisted clarification. Patients routinely describe this time as a time of intense craving and almost certain relapse. The significance is that these two stages of detoxification occur reliably and resonate with each patient s history of previous attempts at naturalistic detoxification over a much longer period of time. The physiology of these stages of detoxification certainly relate to the restoration of receptor and neurotransmitter equilibrium from the state of adaptation that occurs with daily Opioid use. It is the understanding of the author that these periods of sub-acute and post-acute withdrawal that reliably occur in the Naltrexone induced detoxifications also occur in attempts to achieve detoxification by taper or by sudden abstinence, however these stages take much longer without antagonist stimulation. A research question might be, Are these infrequently described and poorly understood sub-acute and post-acute withdrawal states responsible for the poor success rate in detoxification from Opioids? Another significant understanding informed by these observations is that these events will occur following induction of detoxification by any means. Specifically, in a setting where anesthesia-assisted rapid detoxification (Ultra Rapid Opioid Detoxification = UROD) is employed, the symptoms of detoxification would occur and would take as long no matter the dose of Naloxone or Naltrexone administered. The response observed during post-acute and sub-acute withdrawal states on an inpatient unit would predict that discharging a patient prior to the resolution of the anger/agitation/irritability stage would result in frantic attempts to relieve those symptoms by the use of Opioids. This may well explain the tragic results in some patients who have received anesthesia-assisted detoxification and certainly would explain the inability to successfully demonstrate improvement in terms of higher rates of
5 successful participation in abstinence-based treatment or in a lower rate of relapse to the use of opioids for UROD treated patients. As a result of the above experience, which has been accumulated in the treatment with this protocol of over 5,000 patients, the author would not suggest this protocol outside of a locked or potentially locked environment. Patients admitted for detoxification understand in advance that a 5 7 day hospitalization will follow their admission although a smooth experience might result in an earlier transition to a less intensive level of care. Patients are clearly informed that discussions of discharge prior to 72 hours following the administration of the first dose of Naltrexone will not occur. (Fortunately in our setting, should someone choose to leave anyway, law provides that they must request to leave in writing and the period of 72 hours may be utilized to determine if that patient requires involuntary treatment or may be safely discharged at the expiration of that 72 hours.) At issue is the experience of a high probability of relapse to the use of Opioids in the period of post-acute and sub-acute withdrawal. Detoxification from Opioids induced by Naltrexone is never easy and sometimes very uncomfortable. The rationale and justification for this protocol is the frequent fatality and rapid progression of addictive disorder in patients who use Opioids as their drug of choice as well as the great difficulty of completing detoxification through the post-acute phases. However, in the experience described there have been no fatalities within a month of discharge from the inpatient facility. There have been five transfers to the emergency room during detoxification. Two cases have resulted from over-sedation (earlier in the evolution of the protocol), in two cases there was intractable diarrhea with impending dehydration, and there was one case of aspiration pneumonia in a patient who vomited while unobserved. Two of these patients returned to the hospital for completion of the their detoxification and successfully entered abstinence-based treatment. Three of these patients declined the recommendation to return to the hospital. It will be important through retrospective records review, to attempt to determine if patients receiving Naltrexone induced detoxification were able to benefit from abstinence-based treatment at the same frequency and with the same success as patients with addictions to other drugs. If so, this would recommend criteria of completion of detoxification as a defined goal for Opioid addicts attempting abstinence-based treatment. Additionally, it would be important by the design of prospective trials to determine the efficacy of this intervention in the life history of persons with addictive disorder. Our experience has demonstrated that this is a safe protocol in the environment described above. Although critically important, the research questions have yet to be answered.
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationAssessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
More informationCOMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE
COMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE INTRODUCTION High dose sublingual buprenorphine (Subutex) tablets are available in the following strengths 0.4 mg, 2 mg, and 8 mg. Suboxone tablets,
More informationHow To Know If You Should Be Treated
Comprehensive ehavioral Care, Inc. delivery system that does not include sufficient alternatives to a particular LOC and a particular patient. Therefore, CompCare considers at least the following factors
More informationMEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
More informationThe ABCs of Medication Assisted Treatment
The ABCs of Medication Assisted Treatment J E F F R E Y Q U A M M E, E X E C U T I V E D I R E C T O R C O N N E C T I C U T C E R T I F I C A T I O N B O A R D The ABCs of Medication Assisted Treatment
More informationGuidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION
1145 W. Diversey Pkwy. 773-880-1460 Chicago, Illinois 60614 www.ncchc.org Guidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION NCCHC issues guidance to assist correctional health
More informationOpiate Abuse and Mental Illness
visited on Page 1 of 5 LEARN MORE (HTTP://WWW.NAMI.ORG/LEARN-MORE) FIND SUPPORT (HTTP://WWW.NAMI.ORG/FIND-SUPPORT) GET INVOLVED (HTTP://WWW.NAMI.ORG/GET-INVOLVED) DONATE (HTTPS://NAMI360.NAMI.ORG/EWEB/DYNAMICPAGE.ASPX?
More informationBuprenorphine/Naloxone Maintenance Treatment for Opioid Dependence
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
More informationUsing Buprenorphine to Treat Acute Opioid Withdrawal in the ED
Using Buprenorphine to Treat Acute Opioid Withdrawal in the ED Dr. Karine Meador MD CCFP DABAM Assistant Director Inner City Health and Wellness Team Physician Addiction Recovery and Community Health (ARCH)
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationDRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES
01736 850006 www.bosencefarm.co.uk DRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES An environment for change Boswyns provides medically-led drug and alcohol assessment, detoxification and stabilisation.
More informationGuidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care
Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent
More informationTreatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
More informationClinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients
Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,
More informationThis module reviews the following: Opioid addiction and the brain Descriptions and definitions of opioid agonists,
BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module II Opioids 101 Goals for Module II This module reviews the following: Opioid addiction and the brain Descriptions
More information1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
More informationDowners/Depressants (pages 40-50)
Downers/Depressants (pages 40-50) Read pages 49-54, 59-60, and 78-79 of the booklet, Street Drugs. Pages 40-50 of the text. Narcotics: Prescription Origin: Southeast Asia, Southwest Asia, and in the Western
More informationDeath in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
More informationMedications Used in the Treatment of Addiction Developed by Randall Webber, MPH. Alcohol Withdrawal
Medications Used in the Treatment of Addiction Developed by Randall Webber, MPH Alcohol Withdrawal MEDICATION Long/intermediateacting benzodiazepines (e.g., chlordiazepoxide/ Librium, diazepam/valium)
More informationOne example: Chapman and Huygens, 1988, British Journal of Addiction
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
More informationHulpverleningsmodellen bij opiaatverslaving. Frieda Matthys 6 juni 2013
Hulpverleningsmodellen bij opiaatverslaving Frieda Matthys 6 juni 2013 Prevalence The average prevalence of problem opioid use among adults (15 64) is estimated at 0.41%, the equivalent of 1.4 million
More informationLike cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
More informationHeroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
More informationHeroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2011 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationFrequently asked questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
More informationHow To Treat Anorexic Addiction With Medication Assisted Treatment
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
More informationTreatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
More informationUse of Vivitrol for Alcohol and Opioid Addiction
Use of Vivitrol for Alcohol and Opioid Addiction Ken Bachrach, Ph.D. Clinical Director, Tarzana Treatment Centers, Inc. kbachrach@tarzanatc.org What is Vivitrol? An injectable from of naltrexone, which
More informationNaltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
More informationANCILLARY STABILIZATION AND WITHDRAWAL. The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting
ANCILLARY STABILIZATION AND WITHDRAWAL The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting About CASAColumbia A science-based, multidisciplinary organization Focused on transforming
More informationKAP Keys. For Physicians. Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment. of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Knowledge Application Program KAP Keys For Physicians Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine
More informationUse of Buprenorphine in the Treatment of Opioid Addiction
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
More informationNurses Self Paced Learning Module on Pain Management
Nurses Self Paced Learning Module on Pain Management Dominican Santa Cruz Hospital Santa Cruz, California Developed by: Strategic Planning Committee Dominican Santa Cruz Hospital 1555 Soquel Drive Santa
More informationEPIDEMIC 4.6 % OF INDIVIDUALS 18 25 USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationWithdrawal Symptoms: How Long Do They Last?
Withdrawal Symptoms: How Long Do They Last? Posted by First Step Medical Detox on November 24, 2015 When considering stopping drugs or alcohol, many addicts and alcoholics are concerned about the withdrawal
More informationComprehensive Behavioral Care, Inc. Level of Care Guidelines Substance Abuse Children/Adolescents
Medical Necessity In considering the appropriateness of any level of care, the four basic elements of Medical Necessity should be met: 1. A diagnosis as defined by standard diagnosis nomenclatures (DSM
More informationNeurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
More informationReview of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
More informationHeroin. How is Heroin Abused? What Other Adverse Effects Does Heroin Have on Health? How Does Heroin Affect the Brain?
Heroin Heroin is a synthetic opiate drug that is highly addictive. It is made from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears
More informationTHE OFFICE OF SUBSTANCE ABUSE SERVICES REQUIREMENTS FOR THE PROVISION OF RESIDENTIAL DETOXIFICATION SERVICES BY PROVIDERS FUNDED WITH DBHDS RESOURCES
THE OFFICE OF SUBSTANCE ABUSE SERVICES REQUIREMENTS FOR THE PROVISION OF RESIDENTIAL DETOXIFICATION SERVICES BY PROVIDERS FUNDED WITH DBHDS RESOURCES PURPOSE: The goal of this document is to describe the
More informationOpioid Addiction & Methadone Maintenance Treatment. What is Methadone? What is an Opioid?
Opioid Addiction & Methadone Maintenance Treatment Dr. Nick Wong MD, CCFP AADAC Edmonton ODP AADAC AHMB Concurrent Disorder Series September 13, 2007 1 What is Methadone? What is methadone? Synthetic opioid.
More informationMEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT. An Outpatient Model
MEDICALLY SUPERVISED OPIATE WITHDRAWAL FOR THE DEPENDENT PATIENT An Outpatient Model OBJECTIVE TO PRESENT A PROTOCOL FOR THE EVALUATION AND TREATMENT OF PATIENTS WHO ARE CHEMICALLY DEPENDENT ON OR SEVERLY
More informationA G U I D E F O R U S E R S N a l t r e x o n e U
A GUIDE FOR USERS UNaltrexone abstinence not using a particular drug; being drug-free. opioid antagonist a drug which blocks the effects of opioid drugs. dependence the drug has become central to a person
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationOpioid Treatment Services, Office-Based Opioid Treatment
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
More informationOpiate Treatment for Aboriginal High School Students in Ontario
Opiate Treatment for Aboriginal High School Students in Ontario January 2014 1 CHALLENGE About 40% of the students at an Aboriginal high school in Thunder Bay Ontario (Canada) are known to be addicted
More informationDEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM
DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of
More informationOpioid Analgesics. Week 19
Opioid Analgesics Week 19 Analgesic Vocabulary Analgesia Narcotic Opiate Opioid Agonist Antagonist Narcotic Analgesics Controlled substances Opioid analgesics derived from poppy Opiates include morphine,
More informationManagement of Patients with Narcotic Bowel Syndrome(1)
Management of Patients with Narcotic Bowel Syndrome(1) Ademola Aderoju MD, Jacob Kurlander MD, Christina Davis, Patrick Barrett MD, Douglas A. Drossman MD Patients on chronic narcotics who have been diagnosed
More informationIntegrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2015 May 2015 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research
More informationNaloxone treatment of opioid overdose
Naloxone treatment of opioid overdose Opioids Chemicals that act in the brain to relieve pain, often use to suppress cough, treat addiction, and provide comfort After prolonged use of opioids, increasing
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationPrescription Drugs: Abuse and Addiction
EAP Drug Free Workplace Newsletter March 2014 Prescription Drugs: Abuse and Addiction What are some of the commonly abused prescription drugs? Although many prescription drugs can be abused or misused,
More informationConceptualizing and Integrating Medication Assistant Treatment into your Court s Armamentarium
Conceptualizing and Integrating Medication Assistant Treatment into your Court s Armamentarium Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of Medicine tvp@case.edu
More informationUNIT VIII NARCOTIC ANALGESIA
UNIT VIII NARCOTIC ANALGESIA Objective Review the definitions of Analgesic, Narcotic and Antagonistic. List characteristics of Opioid analgesics in terms of mechanism of action, indications for use and
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationDrugFacts: Treatment Approaches for Drug Addiction
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
More informationBuprenorphine: what is it & why use it?
Buprenorphine: what is it & why use it? Dr Nicholas Lintzeris, MBBS, PhD, FAChAM Locum Consultant, Oaks Resource Centre, SLAM National Addiction Centre, Institute of Psychiatry Overview of presentation
More informationMedications for Alcohol and Drug Dependence Treatment
Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram
More informationPain Medication Taper Regimen Time frame to taper off 30-60 days
Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
More informationPutting Addiction Treatment Medications to Use: Lessons Learned
Putting Addiction Treatment Medications to Use: Lessons Learned George E. Woody, M.D. Laura McNicholas, M.D., Ph.D. Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia
More informationMEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Administrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids
More informationBenzodiazepines. And Sleeping Pills. Psychological Medicine
Benzodiazepines And Sleeping Pills Psychological Medicine Introduction Benzodiazepines are a type of medication prescribed by doctors for its therapeutic actions in various conditions such as stress and
More informationTreatments for drug misuse
Understanding NICE guidance Information for people who use NHS services Treatments for drug misuse NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 12/8/2003 Most Recent Review Date (Revised): 3/24/2015 Effective Date: 6/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationDiscontinuation: Involuntary Discharge
Discontinuation: Involuntary Discharge TYPICALLY A PROCESS NOT AN EVENT Objectives 2 Review indications for discharge. Develop a therapeutic approach, in the context of the nature of Substance Use Disorders.
More informationOPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
More informationPrescription Drug Abuse
Prescription Drug Abuse Introduction Most people take medicines only for the reasons their health care providers prescribe them. But millions of people around the world have used prescription drugs for
More informationThe Truth About Suboxone Russell Ferstandig, M.D. Diplomate American Board of Addition Medicine 2014, Russell Ferstandig, M.D., All Rights Reserved
The Truth About Suboxone Russell Ferstandig, M.D. Diplomate American Board of Addition Medicine 2014, Russell Ferstandig, M.D., All Rights Reserved What Is Suboxone And How Is It Different Than Subutex
More informationOpioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification. Original Policy Date
MP 3.01.02 Opioid Antagonists Under Heavy Sedation or General Anesthesia as a Technique of Opioid Detoxification Medical Policy Section Mental Health Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationEPIDEMIOLOGY OF OPIATE USE
Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationAlcohol Withdrawal Syndrome & CIWA Assessment
Alcohol Withdrawal Syndrome & CIWA Assessment Alcohol Withdrawal Syndrome is a set of symptoms that can occur when an individual reduces or stops alcoholic consumption after long periods of use. Prolonged
More information2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California FRIDAY, FEBRUARY 6, 2015: 9:30am - 10:30am Opioid Addiction and Buprenorphine Use * Presented by
More informationOTC Abuse. Dr. Eman Said Abd-Elkhalek Lecturer of Pharmacology & Toxicology Faculty of Pharmacy Mansoura University
OTC Abuse Dr. Eman Said Abd-Elkhalek Lecturer of Pharmacology & Toxicology Faculty of Pharmacy Mansoura University Opiates Abuse Opioids are a group of natural, partially synthetic, or synthetic drugs
More informationBUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS NIDA/SAMHSA Blending Initiative According to the Webster Dictionary definition To Blend means: a. combine into an integrated
More informationBenzodiazepines: A Model for Central Nervous System (CNS) Depressants
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating
More informationGUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: Frenchay 0117 340 6692 Southmead 0117 323
More informationIt is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.
MEDICATION GUIDE VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) Read this Medication Guide before you start receiving VIVITROL injections and each time you receive an injection.
More informationReintegration. Recovery. Medication-Assisted Treatment for Alcohol Dependence. Reintegration. Resilience
Reintegration Recovery Medication-Assisted Treatment for Alcohol Dependence Reintegration Resilience 02 How do you free yourself from the stress and risks of alcohol dependence? Most people cannot do it
More informationConsiderations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
More informationFrequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently
More information10/28/2014. Collecting the Raw Opium
Opioid Analgesics (or Narcotic Analgesics) We are moving on to a new category of drugs whose effects, superficially, may look similar to those of the CNS depressants, but the drugs are, in fact, a completely
More informationMedications for chronic pain
Medications for chronic pain When it comes to treating chronic pain with medications, there are many to choose from. Different types of pain medications are used for different pain conditions. You may
More informationOpioid Agreement for Center for Pain Management S.C.
Opioid Agreement for Center for Pain Management S.C. Patient Name: DOB: I am the patient named above. I have agreed to use pain medication as part of my treatment for chronic pain. I understand that these
More informationOpiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
More informationIdentifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -2/11/13
Identifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -// What is Neonatal Abstinence Syndrome? Neonatal withdrawal after intrauterine exposure
More information5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome
5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279 Welcome Welcome to Starlight Behavioral Health Opiate Dependence program. At Starlight, we believe that addiction is
More informationPRESCRIPTION DRUG ABUSE prevention
PRESCRIPTION DRUG ABUSE prevention Understanding Drug Addiction Many people do not understand how someone could abuse drugs even when their life seems to be falling apart. It is often assumed that those
More informationOpioid Treatment Agreement
Opioid Treatment Agreement 1. I understand that my provider and I will work together to find the most appropriate treatment for my chronic pain. I understand the goals of treatment are not to eliminate
More informationDetoxification. Dr Keron Fletcher Shropshire
Detoxification Dr Keron Fletcher Shropshire 1 Stages of treatment Getting stable Staying stable Detoxifying (withdrawing) Staying drug-free 2 Getting stable Medical right dose of methadone/sbx Holds for
More informationORDER OF EMERGENCY SUSPENSION OF LICENSE
Final Order No. DOH-I -2295- QA FILED DATE -R AA Department of Health STATE OF FLORIDA DEPARTMENT OF HEALTH In Re: Emergency Suspension of the License of By Deputy Agency Clerk ORDER OF EMERGENCY SUSPENSION
More informationOpioid Dependence. Average Purity of Retail Heroin Street Samples in U.S
Opioid Dependence Andrew J. Saxon, M.D. University of Washington, Seattle VA Puget Sound Health Care System Average Purity of Retail Heroin Street Samples in U.S 4 35 3 25 2 15 1 5 198's 1991 2 Source:
More informationOctober 2012. We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely,
October 2012 he Knowledge and Attitudes Survey Regarding Pain tool can be used to assess nurses and other professionals in your setting and as a pre and post test evaluation measure for educational programs.
More informationRECOVERY: Heroin and Rx Opioids. Stan DeKemper Executive Director ICAADA
RECOVERY: Heroin and Rx Opioids Stan DeKemper Executive Director ICAADA 1 GOALS Understand opioid addiction and recovery Identify best practices for opioid addiction treatment Recognize medications approved
More information